165 related articles for article (PubMed ID: 37983933)
1. Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.
Li W; Zhang H; Zhang Y; Wang K; Hui J; Yi Z
CNS Neurosci Ther; 2024 Apr; 30(4):e14531. PubMed ID: 37983933
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Baba Y; Futamura A; Kinno R; Nomoto S; Takahashi S; Yasumoto T; Osakabe Y; Shoji D; Nabeshima Y
J Neurol Sci; 2022 Jun; 437():120263. PubMed ID: 35462236
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis.
Chen X; Ren C; Li J; Wang S; Dron L; Harari O; Whittington C
Clin Neuropharmacol; 2020; 43(4):100-106. PubMed ID: 32658035
[TBL] [Abstract][Full Text] [Related]
5. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
[TBL] [Abstract][Full Text] [Related]
6. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
7. Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Ong TL; Dal S; Martin AJ; Chang FC; Williams LJ; Babu S; Mahant N; Morales-Briceno H; Fletcher N; Nankervis J; Robbie M; Fung VSC
Parkinsonism Relat Disord; 2021 May; 86():84-90. PubMed ID: 33894560
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-Parkinson medication during pregnancy: a case series.
Tüfekçioğlu Z; Hanağası H; Yalçın Çakmaklı G; Elibol B; Esmeli Tokuçoğlu F; Kaya ZE; Ertan S; Özekmekçi S; Emre M
J Neurol; 2018 Aug; 265(8):1922-1929. PubMed ID: 29926223
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Jiang DQ; Zang QM; Jiang LL; Wang Y; Li MX; Qiao JY
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1893-1905. PubMed ID: 33959780
[TBL] [Abstract][Full Text] [Related]
10. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
13. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Gerlach M; Halley P; Riederer P; van den Buuse M
J Neural Transm (Vienna); 2013 Jan; 120(1):31-6. PubMed ID: 22592937
[TBL] [Abstract][Full Text] [Related]
14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
[TBL] [Abstract][Full Text] [Related]
17. Comparison chart: Drugs for Parkinson's disease.
Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
[No Abstract] [Full Text] [Related]
18. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
19. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Lang AE; Rodriguez RL; Boyd JT; Chouinard S; Zadikoff C; Espay AJ; Slevin JT; Fernandez HH; Lew MF; Stein DA; Odin P; Fung VS; Klostermann F; Fasano A; Draganov PV; Schmulewitz N; Robieson WZ; Eaton S; Chatamra K; Benesh JA; Dubow J
Mov Disord; 2016 Apr; 31(4):538-46. PubMed ID: 26695437
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
